Skip to content

Betahistine Mesylate

Published: July 26, 2026Updated: August 27, 2026

Betahistine Mesylate is a histamine analog primarily used to treat vestibular disorders, particularly Ménière's disease. It helps reduce the frequency and severity of vertigo attacks, as well as associated symptoms like tinnitus and hearing loss. The medication works by improving blood flow to the inner ear and reducing vestibular symptoms.

Quick summary

Betahistine Mesylate is used to treat vertigo, tinnitus, and hearing loss associated with Ménière's disease by improving inner ear blood flow.

Medically reviewed by WellAlly Editorial TeamLast reviewed August 27, 2026Editorial policy

Key facts at a glance

RxNorm
71468
Generic
Betahistine Mesylate
Class
pin-variant
Brands
—
Availability
rx
Lactation
unknown
Routes
—
Forms
—
Regions
US, EU, CN, JP
Monitoring
—

This page is for informational purposes only.

Do not use this information to diagnose yourself or to replace a physician's advice. Always consult a qualified healthcare provider before starting, stopping, or changing any medication. If you believe you are experiencing a medical emergency, call your local emergency number immediately.

Betahistine Mesylate is primarily indicated for the treatment of Ménière's disease, a disorder of the inner ear characterized by episodes of vertigo, tinnitus (ringing in the ears), hearing loss, and a sensation of fullness in the ear. It is used to reduce the frequency and severity of vertigo attacks.

Betahistine mesylate acts as a histamine H1 receptor agonist with weak H3 antagonist properties. It works by improving blood flow to the inner ear (cochlear and vestibular circulation), reducing endolymphatic pressure, and modulating vestibular function. This helps alleviate the vertigo and balance disturbances associated with inner ear disorders.

Betahistine is typically taken orally and is usually started at a low dose that may be gradually increased. Common side effects may include headache, nausea, and mild stomach upset. It is generally contraindicated in patients with pheochromocytoma, active peptic ulcer disease, or asthma. Patients should follow their healthcare provider's dosing instructions carefully and report any persistent or worsening symptoms.

Official drug label

WellAlly may earn a referral fee from linked resources at no extra cost to you. Editorial content is never influenced by commercial relationships.

This information is for educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment.

Medical Disclaimer

This content is for general informational and educational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always seek the guidance of a qualified healthcare provider with any questions you have about a medical condition, and never disregard professional medical advice or delay seeking it because of something you read here.

If you think you may have a medical emergency, call your local emergency number or go to the nearest emergency department immediately.

Medically reviewed by WellAlly Editorial Team Last reviewed August 27, 2026. · Read our editorial policy